BCM
TLIS

Bridgeway Capital Management’s Talis Biomedical Corporation Common Stock TLIS Stock Holding History

Bridgeway Capital Management’s Portfolio TLIS Stock Details TLIS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-3,600
Closed -$76K – 1393
2022
Q1 		$76K Buy
3,600
+1,433
+66% +$49.6K ﹤0.01% 1276
2021
Q4 		$130K Buy
+2,167
New +$162K ﹤0.01% 1200

Other funds holding TLIS

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
GC
Greenlight Capital New York $2.05B AUM 78.75% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
PCM
Prelude Capital Management New York $1.31B AUM 62.01% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Bridgeway Capital Management's TLIS Position: Q2 2022 in Review

Bridgeway Capital Management sold out of Talis Biomedical Corporation Common Stock (TLIS) in Q2 2022, closing a stake of 3,600 shares — an estimated $76K sold.

Bridgeway Capital Management first reported a position in TLIS in Q4 2021 and held it in 2 quarters. The position peaked at $130K in Q4 2021. 35 funds tracked by Wall St. Rank hold TLIS as of Q2 2022.

  • Bridgeway Capital Management reported no remaining Talis Biomedical Corporation Common Stock position as of Q2 2022 after selling out during the quarter.
  • Bridgeway Capital Management sold 3,600 Talis Biomedical Corporation Common Stock shares in Q2 2022, an estimated $76K.
  • Bridgeway Capital Management first reported a position in Talis Biomedical Corporation Common Stock in Q4 2021 and held it in 2 quarters.
  • Bridgeway Capital Management's Talis Biomedical Corporation Common Stock position peaked at $130K in Q4 2021.
  • 35 funds tracked by Wall St. Rank held Talis Biomedical Corporation Common Stock as of Q2 2022.

Based on Bridgeway Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.